CareDx

Yahoo Finance • last month

CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference

CareDx logo Key Points Market leadership and solution selling: CareDx said it supports more than 200 transplant centers (~80% of U.S. centers), has performed over 1 million tests, and sees centers using three or more solutions generate r... Full story

Yahoo Finance • 5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

The U.S. stock market recently experienced a rebound, with major indices such as the Nasdaq, Dow Jones Industrial Average, and S&P 500 closing higher amid a recovery from a tech sector downturn and ongoing economic uncertainty due to the g... Full story

Yahoo Finance • 5 months ago

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as... Full story

Yahoo Finance • 5 months ago

CareDx raises 2025 revenue guidance to $372M–$376M with robust RCM gains and new product launches

Earnings Call Insights: CareDx, Inc. (CDNA) Q3 2025 MANAGEMENT VIEW * John Hanna, President and CEO, reported "a strong third quarter on many fronts, including record volume and record revenue in testing services, patient and digital s... Full story

Yahoo Finance • 7 months ago

Implied XBI Analyst Target Price: $142

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 8 months ago

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opp... Full story

Yahoo Finance • 8 months ago

CareDx stock price target lowered to $22 at BTIG on Medicare reimbursement concerns

Investing.com - BTIG has lowered its price target on CareDx, Inc (NASDAQ:CDNA) to $22.00 from $26.00 while maintaining a Buy rating on the stock, citing potential impacts from recent Medicare reimbursement proposals. The stock, currently t... Full story

Yahoo Finance • 8 months ago

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif., August 12, 2025--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William... Full story

Yahoo Finance • 8 months ago

CareDx appoints new CFO

* CareDx (NASDAQ:CDNA [https://seekingalpha.com/symbol/CDNA]) has appointed Nathan Smith as its new chief financial officer. * Smith brings over 14 years of experience in molecular diagnostics, including senior roles at Myriad Genetics... Full story

Yahoo Finance • 8 months ago

CareDx Inc (NASDAQ:CDNA) Posts Mixed Q2 2025 Results Amid Revenue Adjustments and Testing Growth

CAREDX INC (NASDAQ:CDNA [https://www.chartmill.com/stock/quote/CDNA]) REPORTS Q2 2025 EARNINGS: MIXED RESULTS AMID REVENUE ADJUSTMENTS CareDx Inc, a precision medicine company focused on transplant diagnostics, reported its second-quarter... Full story

Yahoo Finance • 8 months ago

CareDx Non-GAAP EPS of $0.10 misses by $0.02

* CareDx press release [https://seekingalpha.com/pr/20191798-caredx-announces-second-quarter-2025-financial-results] (NASDAQ:CDNA [https://seekingalpha.com/symbol/CDNA]): Q2 Non-GAAP EPS of $0.10 misses by $0.02. * Reported revenue of... Full story

Yahoo Finance • 9 months ago

CareDx rebounds as draft LCD suggests no change in coverage

[Cooler for human organ on orange background] Talaj/iStock via Getty Images Following a ~38% sell-off in the previous session, CareDx (NASDAQ:CDNA [https://seekingalpha.com/symbol/CDNA]) traded higher on Friday after the company said it d... Full story

Yahoo Finance • 9 months ago

CareDx Q2 2024 presentation: Revenue jumps 31%, company raises full-year guidance

Introduction & Market Context CareDx, Inc. (NASDAQ:CDNA) presented its Q2 2024 financial results on July 31, 2024, revealing strong revenue growth and a return to profitability. The transplant diagnostics company reported significant impr... Full story

Yahoo Finance • 10 months ago

CareDx to repurchase 5% of outstanding shares

* CareDx (NASDAQ:CDNA [https://seekingalpha.com/symbol/CDNA]) has completed the repurchase of $50M of its common stock representing approximately 5% of outstanding shares, the company said on Tuesday. * Following the completion of the... Full story

Yahoo Finance • 11 months ago

Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders

SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches o... Full story

Yahoo Finance • last year

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

All Patent Claims Asserted Against CareDx are Found to Be Invalid BRISBANE, Calif., February 25, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of... Full story

Yahoo Finance • last year

Investing in CareDx (NASDAQ:CDNA) a year ago would have delivered you a 187% gain

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! For example, the CareDx, Inc (NA... Full story

Yahoo Finance • 2 years ago

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, hi... Full story

Yahoo Finance • 2 years ago

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing

DOJ Concludes Investigation and Declines to Prosecute BRISBANE, Calif., October 08, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development,... Full story

Yahoo Finance • 2 years ago

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., September 14, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,... Full story